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ABSTRACT 
Inhibitors are those particular molecules that have unique properties to control the function of a disease-causing agent. The review sheet 
discusses the list of inhibitors for every disease and the ideal mechanism to excite the same for a better application and impact. Most of the 
inhibitors in this report are noncompetitive which means that they can survive and give an efficient result to the disease on its own without the 
need for an external inhibitor.  
Keywords: Inhibitors, disease-causing agent, enzymes activity 
 
Article Info: Received 21 Dec 2018;     Review Completed 25 Jan 2019;     Accepted 28 Jan 2019;     Available online 15 Feb 2019 
Cite this article as: 
Zhu X, Role of Inhibitors in Controlling the Diseases , Journal of Drug Delivery and Therapeutics. 2019; 9(1-s):381-383          
http://dx.doi.org/10.22270/jddt.v9i1-s.2269                                           
*Address for Correspondence:  
Xiaochai Zhu, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, PR China, 210023 
 
 
Introduction 
Inhibitors are said to be molecules that establish links with 
enzymes and block its activity. This is ideal for dealing with 
metabolic imbalance1-4. Inhibitors can be competitive, 
uncompetitive and mixed. Every inhibitor can cure different 
diseases. The purpose of this review report is to highlight 
three major inhibitors to cure cancer, Alzheimer’s disease 
and neuro disorders respectively. The identified inhibitors 
are found to bind with the agents that cause the disease to 
the patient’s body.  
Inhibitors for cancer 
The biochemical process implies the interaction between 
proteins. Hypoxia is a condition that can be seen in cases 
involving stroke and chronic kidney failure. Peptidic 
inhibitors tend to perform better regarding inhibition and 
stabilization with the help of the pVHL/HIF-1α inhibitor5-8. 
There are different docking structures followed to increase 
efficiency in the repression. The amide group in this inhibitor 
performs two actions - hydrogen bond donor as well as 
acceptor9-13.  
The docking program is the key to efficient inhibition. Cross-
docking helps to create a healthy crystal structure that is 
ideal for the potential inhibitor to act on it and control the 
functions of the disease-causing agent. The inhibitory 
activity happens against the pVHL/HIF-1α interaction 
between proteins thereby resulting in better binding5-8. 
There is a need to work on the molecular optimization so 
that minimal compounds can assure higher potency and also 
serve as a promising lead compound to control cancer. This 
discovery of new inhibitors can be allowed to interact 
utilizing cascade docking and shape based screening 
methods. 
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Inhibitors for Alzheimer’s disease 
Alzheimer’s disease is a progressive neurological disorder 
that has multiple side effects. So far, there are just two 
inhibitors used namely acetylcholinesterase inhibitor and N-
methyl-D-aspartate receptor14-19. The multi-target directed 
ligands tend to contain multi-functional acetylcholinesterase 
inhibitors (AChEIs). After a shape-based virtual screening 
test, it has been observed that T5369186 is a cholinesterase 
inhibitor that can be used to treat cancer and other 
degenerative diseases6. To see the effectiveness of AChE, in 
vitro test followed by molecular docking is performed.  
Molecular docking method is used to observe the 
relationships and activities between two or more 
compounds5-8,20-24. The amino chains are assessed here for 
their interactions. During the test followed by analysis, it was 
observed that 4-aminoquinoline is the core to create new 
cholinesterase inhibitors. This inhibitor is already in use to 
treat Alzheimer’s disease. This can be altered with the 
movement of quinolone to different positions to check the 
specific location/ core that can create multifunctional 
AChEIs6.  
The use of AChEI helps to develop the inhibitory potency, 
and the molecular design is well structured. Irrespective of 
the compounds present, AChEI can penetrate deeper and 
bind with other nano-molecules. Additionally, this inhibitor 
can to control the inflammatory condition associated with 
the nervous system and offers better relief thereby creating a 
normal situation in the affected area. Novel inhibitors are 
required shortly to control similar such progressive 
disorders25-32.  
Inhibitors for melanoma 
To treat skin pigmentation and melanoma, targeting of 
tyrosinase is performed so far. Melanin is a continuous 
production process that damages the skin due to exposure to 
radiation. Tyrosinase acts as an enzyme meant to control 
melanogenesis. With the widespread presence of melanoma, 
it is seen that there is an overexpression of tyrosinase33-40. 
This has led to the growth of dopamine which in turn 
produces dopamine quinone and dopaquinone5. Still, there is 
a need to identify new tyrosinase inhibitors.  
For this process, shape-based overlays are used. The rapid 
overlays align between the molecules and have unique 
features including hydrophobes, rings, hydrogen bond 
acceptor and donor. The best way to determine the novel 
inhibitors for melanoma is to perform virtual screening. This 
is a natural process, but there are drawbacks as well such as 
poor availability, poor activity, and selectivity. The virtual 
screening also determines novel inhibitors that have lower 
cytotoxicity. The identified tyrosinase inhibitor indexed as 
5186-0429 is found to eliminate inflammation and improve 
the resistance with its kinetic and molecular properties. This 
inhibitor can act as a quick heal to the case of melanoma25-29.  
Inhibitors for heart disease 
Another inhibitor/ mediator to protect the cardiac activity of 
a person is protein kinase C. It is already known that 
adenosine helps in cardioprotection. To know more about 
this inhibitor, the signaling mechanism is used, and this 
mechanism also helps to reveal the properties involved in 
the control of mitochondria10. Adenosine receptor activation 
can help to translocate protein kinase C isoforms and the 
latter will in turn bind with caveolin scaffolding. This can 
eliminate the blockages present in the pathway10.  
As cardioprotection is influenced by age factors, the success 
of mitochondrial translocation is still unknown. There is a 
need for a natural inhibitor that can induce adenosine and 
target the right PKC isoforms that can protect from ischemic 
injury and other cardiac diseases.  
Conclusion 
Every inhibitor that is seen in today’s health environment 
has multiple functions. Such inhibitors stand as the 
foundation to control many diseases including heart, 
melanoma, Alzheimer’s and cancer. This paper has produced 
a list of inhibitors and the method to discover novel 
inhibitors that can help achieve a better cure to the disease5-
8. The excitation, screening, docking, and application vary 
from one inhibitor to the other, but all the inhibitors above 
are safe to use to treat the patients and also expect long-term 
results.  
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